Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study

•Bezlotoxumab (BEZ) is more effective than standard of care alone in preventing the recurrence of Clostridioides difficile infection (rCDI).•BEZ reduces the risk of rCDI by 60% in a selected population with multiple risk factors.•This reduction is more evident considering a composite outcome (rCDI and/or death).•BEZ is effective regardless of age, type of standard of care, number of risk factors, and previous Clostridioides difficile infection.•In patients aged <70 years and treated with fidaxomicin, the benefit of BEZ is attenuated.